YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells

Future Oncology

Volumn 5, Issue 2, 2009, Pages 153-156

  Fujii, Teruhiko ^a   Seki, Naoko ^b   Namoto Matsubayashi, Rota ^a   Takahashi, Hiroki ^a   Inoue, Yuka ^a   Toh, Uhi ^b   Kage, Masayoshi ^b   Shirouzu, Kazuo ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; STAT3 PROTEIN; Y BOX BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 66949135008     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.2.153     Document Type: Article

References (9)

1. Lee C, Dhillon J, Wang MY et al.: Targeting YB-1 in HER-2 overexpressing breast cancer cells-induces apoptpsis via the m-TOR/ STAT-3. pathway and suppresses tumor growth in mice. Cancer Res. 69(21), 8661-8666 (2008).
2. Sørlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
3. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
4. Kuwano M, Oda Y, Izumi H et al.: The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol. Cancer Ther. 3(11), 1485-1492 (2004).
5. Habibi G, Leung S, Law JH et al.: Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 10, R86 (2008).
6. Fujii T, Kawahara A, Basaki Y et al.: Expression of ErbB2/HER2 and estrogen receptor α depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 68(5), 1504-1512 (2008).
7. Yu H, Kortylewski M,Pardoll D: Crosstalk between tancer asid immune rells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7(1), 41-51 (2007).
8. Cowley S, Paterson H, Kemp P et al.: Activation ofMAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77(6), 841-852 (1994)
9. Zhou J, Wulfkuhle J, Zhang H et al.: Activation of the PTEN/mTOR/ STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl Acad. Sci. USA 104(41), 16158-16163 (2007).